The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.